Shares of Denali Therapeutics (DNLI) spiked in the premarket on Thursday as the company announced a $195M deal to sell its rare pediatric disease priority review voucher gained from its recent FDA approval.
The FDA has created the Priority Review Newsletters for Every Investor Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities
Subscribe to Newsletters To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser